
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. The company …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

